GlassScriptPhysician profile
Rachel L Cline
NPI 1003308958
$8,486.30
in general payments reported to CMS, 2019-2025
43 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.02 · 2021: $285 · 2022: $1,666 · 2023: $2,153 · 2024: $2,408 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,049 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,049.25 |
| Education | $389.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,154.86 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $862.52 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $813.16 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $650.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $614.08 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $478.26 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $429.26 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $360.92 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $356.89 | 2021-2024 | Belsomra, Steglatro, Gardasil |
| Astellas Pharma US INC | $353.82 | 2022-2025 | Veozah, Myrbetriq |
| Medical Device Business Services, INC. | $325.00 | 2025 | |
| Axsome Therapeutics, INC. | $287.54 | 2023-2025 | Sunosi, Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $279.03 | 2022-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.80 | 2022-2025 | Caplyta |
| Dexcom, INC. | $216.86 | 2023-2025 | Dexcom G6 Transmitter |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.50 | 2023-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $112.46 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.02 | 2020 | |
| Antares Pharma, INC. | $72.33 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $52.94 | 2023-2025 | |
| Glaxosmithkline, LLC. | $48.11 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $33.72 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Tris Pharma INC | $33.48 | 2025 | Dyanavel Xr, Onyda Xr |
| Boston Scientific Corporation | $32.91 | 2023 | Watchman Flx |
| Abbott Laboratories | $32.34 | 2022 | |
| Abiomed | $31.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $28.29 | 2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $25.60 | 2022 | |
| Ardelyx, INC. | $25.36 | 2025 | Ibsrela |
| Corium, LLC | $22.40 | 2023 | Azstarys |
| Jazz Pharmaceuticals INC. | $21.44 | 2021 | |
| Lundbeck LLC | $20.67 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $20.13 | 2025 | Jornay Pm |
| Paratek Pharmaceuticals, INC. | $18.59 | 2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $18.04 | 2021 | |
| Tonix Medicines, INC. | $17.39 | 2025 | Tonmya |
| Acella Pharmaceuticals, LLC | $17.31 | 2025 | NP Thyroid 60 |
| Enterra Medical, INC. | $16.85 | 2024 | |
| Exact Sciences Corporation | $15.90 | 2025 | The Cologuard Plus Collection Kit |
| Tolmar, INC. | $15.81 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $15.16 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $14.07 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $14.05 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.